Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANGIOSWITCH in Metastatic Colorectal Cancer
NCT02075086Phase 2Unknown
- Sponsor
- HM Hospitales
- Start
- Jul 2011
- Primary completion
- May 2015
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in colorectal cancer (CRC), sponsored by HM Hospitales. Primary endpoint: Progression Free Survival at 1 year. Status: unknown.
02
Drugs
bevacizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT02075086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02075086.